GO
Loading...

Pharmaceuticals

More

  • Biovail's Travails Drag "60 Minutes" Into Controversy Thursday, 27 Mar 2008 | 4:09 PM ET
    BIOVAIL

    The Columbia Journalism Review, the pre-eminent publication and authority on what we in the business refer to as "The Big J"--as in Journalism--is calling out CBS' "60 Minutes" in an article just posted on the web with the somewhat explosive headline, "60 Minutes Blows Biovail Story."

  • J&J, Boston Scientific, Medtronic & Abbott: Stent "Stuff" Thursday, 27 Mar 2008 | 10:50 AM ET
    Heart Stent

    Ahead of the world's biggest gathering of cardiologists in Chicago this weekend, there's a flurry of news about stents--the expensive little wire mesh tubes that prop open clogged arteries. First, the Food and Drug Administration has posted new proposed guidelines for pre-and post-market testing of the controversial devices.

  • Bear Stearns' Amgen Call  Brings On More Gallows Humor Wednesday, 26 Mar 2008 | 1:16 PM ET

    This morning, Bear Stearns biotech analyst Mark Schoenebaum and a couple of members of his research team hosted a conference call with a 50-page PowerPoint about Amgen. The purpose was to drill down into the looming court decision over whether Roche will be able to launch a competing anemia drug in the U.S. for kidney dialysis patients.

  • Big Pharma Power Shift: CFOs May Have The Mojo Now Wednesday, 26 Mar 2008 | 11:01 AM ET

    Big pharma CEOs might wanna watch their backs because there could be a burgeoning power struggle in the C-suite. Ernst & Young, which has a long history of doing comprehensive reports on the pharmaceutical and biotech industries, is out with a new one today declaring that it's big pharma Chief Financial Officers who have all the mojo these days.

  • FDA's Internet Facelift Still A Work In Progress Tuesday, 25 Mar 2008 | 4:47 PM ET
    FDA

    If you haven't seen it yet, check out the new homepage of the Food and Drug Administration web site www.fda.gov. The agency unveiled it the other day. The interior of the web site still looks pretty much the same.

  • J&J, Merck & Wyeth Tops in Big Pharma CEO Pay Tuesday, 25 Mar 2008 | 11:31 AM ET

    As proxy statements pop up on www.sec.gov, investors can get a peek at who's making what. When you go to the web site, click on "Search for company filings," then click on "Companies and other filers," enter the ticker symbol, click on "Find companies" and then open up the "14A" or proxy statement.

  • Biovail's Travails And The "Haunting" Truck Accident Monday, 24 Mar 2008 | 4:12 PM ET
    BIOVAIL

    Shares of Canada's biggest biotech initially hit a new intra-day low this morning of 10 bucks a share this morning, but rallied into the close as investors seem to like the fact that the company may have extricated itself from allegations of financial fraud.

  • Gilead Sciences "Pushes Out" Amgen As Number 2 Biotech Monday, 24 Mar 2008 | 12:40 PM ET

    Investors now think that a biotech company with less than one-third the revenue of Amgen is worth more than the former sector king. Elizabeth Trotta at TheStreet.com took note of this late last week but I thought it was worth pointing out.

  • These days there's been a lot of media attention paid to the Merck and Schering-Plough partnership on the cholesterol-fighting drugs Zetia and Vytorin. But there's another less-known and little-talked-about respiratory MRK/SGP joint venture.

  • ACC: Can It "Enhance" Merck And Schering-Plough? Wednesday, 19 Mar 2008 | 2:54 PM ET

    The American College of Cardiology held a telephone press briefing this afternoon to help get reporters up to speed on potential headline-grabbing studies that researchers will present at the annual ACC meeting in Chicago at the end of this month.

  • Merck And Big Pharma: Both Getting A Stock "Booster" Shot? Wednesday, 19 Mar 2008 | 11:14 AM ET
    Gardasil

    Merck this morning announced that it has filed for Food and Drug Administration approval of its blockbuster cervical cancer vaccine, Gardasil, for women 27-45 years old. Right now it's approved for females 9-26.

  • Lightning Round: Wachovia, Crocs, Ford and More Tuesday, 18 Mar 2008 | 7:03 PM ET

    Cramer makes the call on viewers' favorite stocks.

  • Amgen And Its Rather Anemic Stock Performance Tuesday, 18 Mar 2008 | 11:54 AM ET

    Shares of Amgen closed just above 43 bucks yesterday. That's more than a five-year low. And they're falling even lower in early trading this morning. Today the company is making its first investor presentation since last week's FDA advisory committee vote to restrict usage of Amgen's anemia drugs on cancer patients.

  • Genentech: Top O The Mornin' This St. Patty's Day Monday, 17 Mar 2008 | 10:03 AM ET

    This St. Patrick's Day morning several analysts are out with their official takes on Genentech's investor meeting last Friday and of the half dozen or so I've seen so far, I'd say the reaction is definitely mixed. I also wanted to throw in a few more notable quotables from CEO Art Levinson at the Friday presentation.

  • The Return of Big Pharma Friday, 14 Mar 2008 | 6:44 PM ET

    This could be the sector to own by next fall's presidential election.

  • Genentech And The Bear Stearns Bailout Friday, 14 Mar 2008 | 3:14 PM ET

    So guess which analyst happened to be selected first to query Genentech management at the start of the Q and A portion of the biotech company's analyst meeting? Yep. Mark Schoenebaum from Bear Stearns.

  • I am at the Genentech analyst meeting at the Mandarin Oriental Hotel next to the new Time Warner Center in Columbus Circle in Manhattan. The room is packed with an estimated 300-plus analysts, investors, reporters and Genentech execs.

  • UK Drug Maker Shire Jumps on Talk of Pfizer Bid Friday, 14 Mar 2008 | 6:59 AM ET

    Shares in British drugmaker Shire leapt as much as 10 percent on Friday, as traders  eportedtalk of bid interest from U.S. rival Pfizer.

  • Amgen, JNJ Get Somewhat Mixed Message From FDA Panel Thursday, 13 Mar 2008 | 4:32 PM ET

    Amgen, the world's biggest biotech company in terms of sales (Genentech dwarfs Amgen in market cap: $86 billion vs. $51 billion) and Dow component Johnson & Johnson avoided a worst-case scenario this afternoon.

  • Genentech In 2007: Stock Ends Down, Exec Comp Goes Up Thursday, 13 Mar 2008 | 12:26 PM ET

    Last year Genentech shares traded as high as nearly 88 dollars, but ended 2007 around 67 bucks. But according to the company's new proxy statement all of Genentech's top-tier executives saw their total compensation go up.